hepat
b
viru
hbv
infect
wide
distribut
throughout
world
least
million
peopl
hbv
carrier
high
risk
develop
hepat
decompens
cirrhosi
hepatocellular
carcinoma
strong
polyclon
cell
respons
essenti
clearanc
hbv
infect
liver
therefor
patient
receiv
immunosuppress
therapi
may
potenti
high
risk
hbv
infect
due
lack
adequ
immun
hbv
reactiv
immunosuppress
therapi
occur
frequent
patient
chronic
resolv
hbv
infect
rare
report
hbv
seroneg
patient
hbv
recurr
liver
transplant
occur
patient
without
prevent
occur
patient
prophylact
treatment
use
hepat
b
immunoglobulin
hbig
nucleosidenucleotid
analog
na
although
hbig
na
hepat
b
vaccin
effect
prevent
treat
hbv
reactiv
recurr
mani
factor
remain
unresolv
exampl
patient
immunosuppress
therapi
poor
respons
rate
hepat
b
vaccin
strategi
prophylaxi
treatment
hbv
reactiv
recurr
optim
detail
analysi
hbv
infect
immunosuppress
essenti
resolv
abovement
problem
hbv
research
use
mous
model
transient
persist
hbv
replic
establish
base
techniqu
call
hydrodynam
inject
hi
use
assess
effect
vaccin
examin
relationship
type
immun
respons
hbv
clearanc
given
hi
balbc
mice
lead
transient
hbv
replic
gene
express
liver
system
could
use
analyz
influenc
immunosuppress
agent
hbv
replic
four
wide
use
immunosuppress
drug
select
corticoid
dexamethason
dex
calcineurin
inhibitor
cyclosporin
csa
alkyl
agent
cyclophosphamid
cyp
antimetabolit
mycophenol
mofetil
mmf
use
immun
compet
mous
model
hbv
hi
demonstr
hbv
replic
immunosuppress
therapi
extend
treatment
immunosuppress
agent
transient
treatment
csa
cyp
led
longterm
hbv
persist
high
level
viral
replic
notabl
mrna
level
cell
marker
cytokin
express
liver
significantli
suppress
csa
treatment
restor
earli
withdraw
csa
indic
impair
immunolog
function
hepat
compart
lead
hbv
persist
furthermor
adopt
immun
transfer
led
hbv
suppress
femal
balbc
mice
week
age
purchas
center
diseas
control
hubei
china
kept
specif
pathogenfre
condit
experiment
anim
centr
tongji
medic
colleg
huazhong
univers
scienc
technolog
studi
perform
strict
accord
recommend
guid
care
use
laboratori
anim
nation
institut
health
protocol
approv
institut
anim
care
use
committe
tongji
medic
colleg
huazhong
univers
scienc
technolog
permit
number
surgeri
perform
sodium
pentobarbit
anesthesia
everi
effort
made
minim
suffer
immunosuppress
agent
salin
administ
intraperiton
week
prior
hi
follow
dose
volum
ml
dex
hubei
tianyao
pharma
china
mgkgd
csa
novarti
germani
cyp
baxter
germani
mmf
roch
germani
dilut
salin
gavag
administ
week
prior
hi
dose
mgkgd
mice
receiv
hi
kindli
provid
prof
chen
pj
graduat
institut
clinic
medicin
colleg
medicin
nation
taiwan
univers
describ
previous
immun
donor
mice
inject
intramuscularli
phbc
describ
previous
splenocyt
immun
donor
mice
prepar
describ
previous
hbvpersist
mice
treat
csa
week
left
control
inject
intraven
splenocyt
immun
donor
mice
week
w
hi
serum
sampl
dilut
diluent
univers
roch
diagnost
switzerland
hepat
b
viru
surfac
antigen
hbsag
hepat
b
viru
surfac
antibodi
hbsab
hepat
b
viru
core
antibodi
hbcab
detect
use
electrochemiluminesc
immunoassay
eclia
system
roch
diagnost
switzerland
accord
manufactur
instruct
percentag
inhibit
hbcab
calcul
formula
index
calibr
mean
rate
sampl
rate
index
calibr
mean
rate
hbv
dna
level
quantifi
realtim
polymeras
chain
reaction
pcr
use
sybr
green
dye
describ
previous
follow
primer
use
forward
primer
cat
cct
gct
gct
nt
revers
primer
tga
aca
aat
ggc
nt
base
refer
sequenc
genbank
access
number
serum
sampl
contain
known
concentr
hbv
dna
use
posit
control
total
dna
extract
liver
sampl
use
tissu
dna
kit
omega
usa
analyz
southern
blot
use
fulllength
hbv
probe
describ
previous
liver
sampl
collect
embed
paraffin
routin
section
stain
rabbit
antihbv
core
antigen
hbcag
polyclon
antibodi
dako
japan
visual
dako
detect
system
dako
japan
accord
manufactur
instruct
splenocyt
separ
ficol
densitygradi
centrifug
accord
manufactur
instruct
dakew
china
splenocyt
cultur
densiti
cell
per
well
presenc
recombin
hbsag
rhbsag
recombin
hbcag
rhbcag
unrel
cmv
peptid
prospectani
china
concentr
splenocyt
cultur
medium
cona
invitrogen
usa
serv
neg
posit
control
respect
elispot
assay
perform
use
mous
precoat
elispot
kit
dakew
china
accord
manufactur
instruct
spot
count
use
immunospot
analyz
support
immunospot
softwar
cellular
technolog
usa
result
present
spotform
cell
per
cell
mrna
level
cd
molecul
cytokin
measur
realtim
reversetranscript
pcr
use
sybr
green
dye
briefli
total
rna
extract
mous
liver
sampl
use
trizol
reagent
invitrogen
usa
rel
mrna
level
paramet
analyz
use
quantifast
sybr
green
pcr
kit
quantitect
primer
qiagen
germani
accord
manufactur
instruct
quantif
perform
use
pfaffl
method
calcul
copi
number
ctvalu
gene
per
sampl
mrna
level
calcul
manner
use
normal
express
level
select
gene
given
copi
copi
mrna
statist
analysi
conduct
use
spss
softwar
version
spss
inc
usa
differ
two
group
among
multipl
group
analyz
twotail
unpair
student
test
oneway
anova
tukey
multipl
comparison
test
respect
p
valu
consid
statist
signific
ensur
compar
transfect
effici
among
immunosuppressanttr
control
mice
level
hbv
dna
hbsag
sera
measur
day
post
hi
level
hbv
dna
hbsag
significantli
differ
salinetr
immunosuppressanttr
mice
fig
analyz
influenc
differ
immunosuppress
hbv
replic
hbsag
hbv
dna
level
dynam
measur
treatment
durat
hbsag
hbv
dna
sera
mice
treat
dex
csa
cyp
maintain
high
level
approxim
cut
index
coi
copiesml
respect
sera
level
hbv
dna
hbsag
mmftreat
mice
decreas
gradual
becam
neg
within
week
post
hi
anim
hbv
dna
neg
anoth
anim
post
hi
fig
contrast
hbv
replic
balbc
mice
usual
ceas
within
week
hbv
dna
becam
neg
within
week
hbsag
elimin
within
week
mice
treat
salin
fig
measur
transient
immunosuppress
treatment
induc
longterm
hbv
persist
hbsag
hbv
dna
level
follow
anoth
week
immunosuppress
discontinu
dextreat
mice
becam
neg
hbv
dna
within
week
dex
withdraw
hbsag
level
decreas
rapidli
maintain
less
coi
week
post
hi
fig
major
csatreat
mice
hbsag
hbv
dna
level
maintain
approxim
coi
copiesml
respect
fig
cyptreat
mice
persist
posit
hbsag
hbv
dna
week
post
hi
high
level
approxim
coi
copiesml
respect
fig
hbv
dna
becam
neg
within
week
mmf
discontinu
anim
addit
hbsag
decreas
slowli
becam
neg
major
mmftreat
mice
wherea
hbsag
hbv
dna
anim
remain
posit
fig
explor
influenc
immunosuppress
hbv
antibodi
respons
hbcab
hbsab
measur
end
treatment
end
followup
hi
hbcab
hbsab
neg
anim
hbcab
detect
control
mice
csatreat
mice
neg
dex
cyp
mmftreat
mice
hbsab
detect
control
mice
neg
immunosuppressanttr
mice
fig
mice
even
becam
neg
hbsag
hbv
dna
fig
investig
time
transient
immunosuppress
treatment
necessari
induc
hbv
persist
csa
select
treat
hi
mice
week
hi
differ
time
point
post
hi
fig
mice
treat
salin
serv
control
post
hi
hbsag
level
compar
control
csatreat
mice
indic
mice
two
group
compar
transfect
effici
fig
control
mice
mice
treat
csa
less
week
post
hi
hbsag
neg
major
mice
treat
csa
post
hi
hbsag
posit
fig
end
observ
period
least
week
csa
withdraw
hbsag
remain
posit
major
mice
treat
csa
fig
data
indic
csa
treatment
week
hi
week
hi
caus
hbv
persist
least
month
analyz
hbv
replic
gene
express
mice
receiv
salin
salin
csa
week
hi
week
post
hi
refer
respect
fig
consist
salinetr
mice
rapidli
clear
hbsag
hbv
dna
peripher
hbsag
hbv
dna
persist
entir
observ
period
mice
hbsag
hbv
dna
level
mice
decreas
csa
withdraw
undetect
three
four
mice
fig
hbv
replic
intermedi
hbcag
mous
liver
examin
southern
blot
analysi
ihc
fig
consist
hbv
marker
peripher
blood
hbv
replic
intermedi
hbcag
liver
present
liver
mice
three
group
becam
undetect
salinetr
mice
mice
respect
remain
detect
mice
hi
hbv
plasmid
predominantli
transfect
liver
lead
hbv
replic
mous
liver
mimic
hbv
replic
human
liver
thu
intrahepat
mrna
level
cell
marker
eg
antivir
cytokin
eg
tumor
necrosi
factor
alpha
cytotox
molecul
eg
fa
ligand
fasl
perforin
quantifi
realtim
reversetranscript
pcr
fig
first
analyz
dynam
chang
molecul
liver
salinetr
mice
result
reveal
level
fasl
perforin
significantli
elev
accompani
decreas
hbsag
hbv
dna
level
serum
viru
ultim
elimin
serum
liver
fig
subsequ
compar
express
molecul
liver
mice
receiv
salin
csa
time
point
decreas
hbv
replic
salinetr
mice
mice
molecul
elev
salinetr
mice
suppress
csatreat
mice
declin
perforin
statist
signific
fig
discontinu
csa
treatment
led
signific
increas
level
perforin
coincid
declin
hbv
replic
hbv
clearanc
fig
transient
csa
treatment
lead
suppress
intrahepat
cell
respons
allow
longterm
hbv
persist
mous
model
adopt
transfer
immun
cell
individu
immun
hbv
infect
boost
host
immun
respons
hbv
publish
clinic
anim
studi
therefor
ask
whether
longterm
hbv
persist
induc
transient
csa
treatment
could
termin
adopt
immun
transfer
three
group
mice
receiv
csa
treatment
week
post
hi
mice
receiv
splenocyt
mice
mice
immun
hbcag
express
plasmid
phbc
immun
left
control
control
fig
transfer
splenocyt
immun
mice
led
signific
decreas
level
serum
hbsag
liver
hbcag
enhanc
hbcab
respons
cellular
respons
hbcag
recipi
mice
fig
wherea
hbsab
remain
undetect
recipi
mice
fig
serum
hbsag
liver
hbcag
persist
detect
control
mice
fig
mice
control
group
except
one
mous
remain
neg
hbsab
fig
hbcab
cellular
respons
hbcag
unchang
mice
group
fig
use
mous
model
acut
hepat
b
replic
demonstr
treatment
four
immunosuppress
differ
effect
hbv
replic
hbv
replic
elimin
immunosuppressanttr
mice
maintain
high
level
mice
treat
dex
csa
cyp
mmf
although
mice
receiv
regimen
dex
csa
cyp
mmf
treatment
exhibit
compar
extend
surviv
time
skin
graft
fig
withdraw
immunosuppress
treatment
hbv
persist
high
level
csa
cyptreat
mice
low
level
dextreat
mice
furthermor
earli
post
hi
withdraw
csa
treatment
restor
suppress
intrahepat
cell
respons
led
subsequ
hbv
clearanc
final
adopt
transfer
splenocyt
donor
mice
immun
hbcag
express
plasmid
led
hbv
suppress
hbvpersist
mice
present
studi
use
hbv
hi
mice
model
four
immunosuppress
differ
effect
hbv
replic
vivo
consist
effect
immunosuppress
hbv
replic
vitro
eg
csa
suppress
hbv
replic
mmf
could
enhanc
suppress
hbv
replic
depend
content
hbv
infect
addit
compar
situat
hbv
reactiv
organ
transplant
chemotherapi
although
form
immunosuppress
treatment
result
hbv
reactiv
certain
drug
associ
higher
risk
other
eg
steroid
frequent
associ
hbv
reactiv
may
associ
differ
effect
virusspecif
cell
respons
eg
tacrolimu
calcineurin
inhibitor
potent
inhibit
cmvspecif
cytokin
wherea
mmf
preferenti
inhibit
cmvspecif
cytokin
furthermor
mmf
recent
found
inhibit
activ
inosin
monophosph
dehydrogenas
result
decreas
intracellular
level
guanosin
nucleotid
pool
augment
interferonstimul
gene
express
properti
mmf
may
also
contribut
reduct
hbv
dna
mmftreat
mice
although
immunosuppress
benefici
increas
longterm
surviv
patient
organ
transplant
lifelong
administr
immunosuppress
also
yield
numer
side
effect
eg
hbv
reactiv
recurr
discuss
articl
high
risk
infect
pathogen
recent
sever
studi
attempt
evalu
impact
minim
complet
withdraw
immunosuppress
liver
transplant
immunosuppress
success
discontinu
approxim
care
select
recipi
eg
longer
durat
transplant
indic
longterm
immunosuppress
led
toler
transplant
liver
interestingli
present
studi
discontinu
immunosuppress
treatment
alway
result
restor
immunolog
function
subsequ
hbv
clearanc
may
also
suggest
immunosuppress
treatment
use
select
drug
suffici
length
time
caus
toler
hbv
cell
particularli
intrahepat
hbvspecif
cell
play
critic
role
hbv
clearanc
frequenc
hbvspecif
cell
gener
extrem
low
balbc
mice
receiv
hi
could
properli
measur
intracellular
stain
flow
cytometri
analysi
fig
therefor
analyz
intrahepat
mrna
express
molecul
close
relat
cell
immun
respons
includ
cell
marker
eg
antivir
cytokin
eg
cytotox
molecul
eg
fasl
perforin
express
perforin
increas
hbv
transfect
accompani
decreas
hbv
replic
subsequ
hbv
clearanc
consist
find
woodchuck
liver
acut
woodchuck
hepat
viru
infect
although
perforin
also
produc
nk
cell
nkcell
deplet
antiasialo
antibodi
could
prolong
hbv
replic
immunocompet
mice
data
shown
indic
hbv
clearanc
immunocompet
mice
mainli
mediat
perforindepend
cell
respons
result
complet
consist
previou
studi
use
knockout
mice
defici
numer
cellular
molecular
effector
use
knockout
mice
research
found
cell
mediat
hbv
clearanc
fasdepend
perforinindepend
manner
csa
treatment
extend
hbv
replic
suppress
intrahepat
express
perforin
moreov
earli
csa
withdraw
restor
intrahepat
express
perforin
led
hbv
clearanc
liver
therebi
provid
evid
regard
cell
responsemedi
hbv
clearanc
immunocompet
mice
model
note
alter
mrna
express
may
result
differ
event
includ
gener
system
reduct
cell
respons
reduc
liverinfiltr
specif
cell
differ
cell
prolifer
statu
liver
alter
express
profil
singl
cell
level
specif
cellular
immun
respons
hepadnavir
core
antigen
consid
critic
control
hbv
infect
whv
infect
woodchuck
adopt
transfer
splenocyt
mice
immun
hbcag
express
plasmid
effect
enhanc
cellular
respons
hbv
protein
suppress
hbv
replic
hbvpersist
mice
result
consist
clinic
find
patient
liver
transplant
bone
marrow
transplant
adopt
immun
transfer
might
promis
immunotherapeut
approach
patient
hbv
recurr
liver
transplant
taken
togeth
demonstr
immunosuppress
treatment
extend
hbv
replic
caus
longterm
hbv
persist
even
immunosuppress
withdraw
hbv
replic
immunosuppress
depend
immunosuppress
drug
treatment
durat
find
may
help
individu
treatment
immunosuppress
drug
patient
high
risk
hbv
reactiv
recurr
purpos
immunosuppress
agent
tacrolimu
rapamycin
must
also
evalu
system
also
demonstr
impair
intrahepat
cell
respons
may
respons
hbv
persist
immunosuppress
restor
cell
respons
lead
hbv
clearanc
suppress
hbvpersist
mous
model
therebi
mimick
hbv
infect
human
therefor
hbv
mous
model
base
hi
suitabl
studi
hbv
infect
immun
suppress
evalu
optim
approach
prophylaxi
treatment
hbv
reactiv
recurr
immunosuppress
therapi
